European Psychiatry - Volume 41 - April 2017

761 / 916

25th European Congress of Psychiatry / European Psychiatry 41S (2017) S710–S771 S757
assessment: structural clinical interview–SCID, ICD–10; Hamilton
anxiety rating scale–HAM-A, and the self-report scale for assess-
ment of anxiety–state-trait anxiety inventory–STAI-Form Y. The
testing using these instruments was conducted four weeks after
the start of the treatment, then after eight weeks, after 12, 24 and
48 weeks, i.e. at the end of the treatment. The patients in the study
group received 150–300mg of trazodone per day, starting at the
week 6 of interferon treatment.
Results The research showed that in the beginning of the
interferon treatment approximately one quarter of the patients
exhibited symptoms of anxiety in both groups. The administra-
tion of trazodone showed beneficial effects in reduction of anxiety
induced by the treatment with pegylated interferon.
Disclosure of interest The author has not supplied his/her decla-
ration of competing interest.
EV1086
Effectiveness of long-acting
aripiprazole in schizoaffective
disorders: A naturalistic longitudinal
study
A. Nivoli∗, M. Antonioli , L. Folini , L. Floris , G. Meli , M. Paolo ,
L. Lorettu
University of Sassari, Department of Psychiatry, Sassari, Italy
∗ Corresponding author.
Introduction Intramuscular paliperidone palmitate (PP) is a long-
acting, atypical anti-psychotic for oncemonthly intramuscular (IM)
administration in the treatment of patients with schizophrenia.
Objective To study the effectiveness (efficacy and quality of life)
of ARP in the maintenance treatment of schizoaffective disorder.
Methods A non-randomized, prospective naturalistic study was
performed in out-patients with schizoaffective disorder unsuccess-
fully treatedwithoral anti-psychotics. Efficacy of ARP over timewas
evaluated by using brief psychiatric rating scale (BPRS 24-items),
quality of life was evaluated by using QL-Index, both at T0 and at
most recent visit (T1). Data were analyzed with Student’s t-tests
and Pearson correlations ( value, two tailed). Paired t-test was
applied for BPRS and for Ql-Index total scores (T0–T1).
Results Data were available for 8 outpatients consecutively pre-
scribed ARP and naturalistically treated attending at the psychiatric
clinic, university of Sassari. Mean time on ARP treatment was
207.14 days (sd 137.2). BPRS mean total score at T0 was 57 (sd 13.2)
and at T1 was 39.7 (sd 10.8). QL-Index mean total score was at T0
5.43 (sd 1.6) and at T1 7.14 (sd 2.7). Paired sample test showed
a statistically significant difference in decreasing symptoms at
BPRS over time (P = 0.001) and QL-Index total score (P = 0.023). The
analyses showed a significant improving at the following BPRS sub-
items: anxiety (P= 0.005), mood elevation (P = 0.014) conceptual
disorganization (P = 0.048), emotional withdrawal (P= 0.05), ten-
sion (P = 0.02) and distractibility (P = 0.03).
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1087
Successful treatment of OCD-bipolar
co-morbidity with
clozapine – aripiprazole combination
U. Ouali∗, Y. Zgueb , A. Ouertani , F. Nacef
Razi Hospital, Psychiatry A, Mannouba, Tunisia
∗ Corresponding author.
Introduction Co-morbid obsessive-compulsive disorder (OCD) in
bipolar disorder (BD) negatively affects clinical course and out-
come, and considerably complicates its treatment.
Objective To show a therapeutic approach still rarely used in case
of resistant bipolar disorder associated with OCD.
Methods Presentation of the clinical case of Mr. M.H., who
is treated in our department since 2008 for OCD-bipolar co-
morbidity, followed by a literature review.
Results Mr. M.H. is a 29-year-old male patient. He developed BD
associated to OCD at age 20. In order to control bipolar symptoms,
the patient received several trials of anti-psychotics combinedwith
mood stabilizers with little improvement. Resistant BD was diag-
nosed, and clozapine 300mg daily introduced, leading to significant
improvement in bipolar symptoms but worsening in OC symptoms.
Treatment of OCD with fluoxetine and with cognitive-behavioral
therapy (CBT) was unsuccessful. Introduction of aripiprazole 20mg
daily led to decided improvement of OC-symptoms. After one year,
clozapine was gradually tapered down to 150mg daily without
reappearance of bipolar symptoms but further improvement of
OC-symptoms.
Conclusion Treatment of OCD-bipolar co-morbidity is difficult
given the risk of manic switch with antidepressants and the risk
of benzodiazepine dependence. CBT could represent an alternative,
however, it did not show any efficacy in our patient. Worsening of
OCD under clozapine is described in the literature. Adjunction of
aripiprazole to clozapine seems an interesting therapeutic option:
it diminishes OC symptoms without destabilizing the patient’s
mood state.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1088
Interactions between SSRI’s and
statins: Clinical relevance versus
statistical significance
S. Petrykiv ∗ e Jonge Arts
1 University Medical Center Groningen, Department of Clinical
Pharmacy and Pharmacology, Groningen, The Netherlands
2 Leonardo Scientific Research Institute, Department of Geriatric
Psychiatry, Groningen, The Netherlands
3 University Medical Center Groningen, Department of Old Age
Psychiatry, Groningen, The Netherlands
∗ Corresponding author.
Introduction Depression and hypercholesterolemia are two of
the most commonly treated conditions in the developed countries,
while the lipid–lowering agents and antidepressants are among
the most widely prescribed drugs in the world. There is a com-
mon concern that selective serotonin reuptake inhibitors (SSRIs)
can trigger statin adverse effects, especially myopathy. However,
the supporting evidence originates from studies in-vitro and big
epidemiological studies. Recent pharmacokinetic insights indicate
that the magnitude of pharmacokinetic interaction between SSRIs
and statins is likely to be below the threshold for clinical signifi-
cance.
Objectives and aims Explorative study onpharmacokinetic effects
of SSRIs on statin drugs.
Methods We performed a detailed literature review through
PubMed, EMBASE and Cochran’s Library to assess the clinical
relevance of combined SSRIs and statin use. To address pharma-
cokinetic interactions between two drug groups, we focused on:
– cytochrome P450 enzyme metabolism of statins;
– CYP enzyme inhibition by SSRIs;
– SSRIs–statin drug interactions;
– non-CYP pharmacokinetic pathways.
Results With regard to pharmacokinetic drug interactions and
the risk of statin related myopathy, escitalopram, citalopram, and
paroxetine are to be safe in co-therapywith all statins. Rosuvastatin
and pravastatin are almost certain to be safe in co-therapy with all